SCHEMBL2932784

SCHEMBL2932784

FC(F)(F)c1ccc2c(c1)oc1c3cccc(Cl)c3[nH]c21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.57
PIM1 P11309 3/20 0.42
PIM3 Q86V86 3/20 0.42
CSNK2A2 P19784 2/20 0.42
CSNK2B P67870 2/20 0.42
PIM2 Q9P1W9 2/20 0.42
C1R P00736 1/20 0.40
TNKS O95271 1/20 0.40
KIF11 P52732 3/20 0.39
MCL1 Q07820 1/20 0.36
AHR P35869 2/20 0.35
TTR P02766 1/20 0.34
PSMB8 P28062 1/20 0.34
F7 P08709 1/20 0.33
F3 P13726 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
PBRM1 Q86U86 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925140 0.85 KCNMA1 (0.61) KCNMA1PIM1PIM3CSNK2A2CSNK2B
SCHEMBL2930924 0.85 KCNMA1 (0.49) KCNMA1PIM1PIM3CSNK2A2CSNK2B
SCHEMBL2930598 0.81 KCNMA1 (0.46) KCNMA1TNKSKIF11MCL1PSMB8
SCHEMBL2933540 0.80 KCNMA1 (0.67) KCNMA1PIM1PIM2ALDH1A1PBRM1
SCHEMBL12181091 0.78 PSMB8 (0.46) PIM1PIM3CSNK2A2CSNK2BPIM2
SCHEMBL2931881 0.77 KCNMA1 (0.57) KCNMA1PIM1PIM3CSNK2A2CSNK2B
SCHEMBL2931043 0.77 KCNMA1 (0.52) KCNMA1PIM1PIM3KIF11ALDH1A1
SCHEMBL2931271 0.76 KCNMA1 (0.50) KCNMA1KIF11CDK4CCND1
SCHEMBL2934874 0.75 KCNMA1 (0.50) KCNMA1PIM1PIM3KIF11F7
SCHEMBL2925491 0.73 KCNMA1 (0.68) KCNMA1PIM1PIM3CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812177-B2 Potassium channel opener having benzofuroindole skeleton ANYGEN CO., LTD. (KR) 2010-10-12 US disclosed
EP-1861092-B1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2010-09-15 EP disclosed
EP-1861092-A4 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2009-04-15 EP disclosed
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton ANYGEN CO., LTD. (KR) 2008-08-14 US disclosed
EP-1861092-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON Anygen Co., Ltd. (KR) 2007-12-05 EP disclosed
WO-2006096030-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO., LTD. (KR) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton KCNJ2, KCNN3, KCNH2 KCNMA1 41/4885PIM1 3440/4885PIM3 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.